Overview Dividends

(CVS) CVS Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1266501006

Insurance, PBM, Retail, Pharmacy, Wellness

Health Care Services
Market Cap in USD: 98,889m

IPO / Inception: 1984-12-17
Return 12m vs S&P 500: 22.0%

EPS (Earnings per Share)

EPS CAGR: -5.52%
EPS Trend: -52.8%

Last SUE: 0.72
Qual. Beats: 0

Revenue

Rev. CAGR: 8.18%
Rev. Trend: 96.9%

Last SUE: 0.43
Qual. Beats: 0

Dividends

Dividend Yield	3.31%
Yield on Cost 5y	4.61%
Yield CAGR 5y	7.39%
Payout Consistency	92.4%
Payout Ratio	38.8%

Risk via 10d forecast
Volatility	35.5%
Value at Risk 5%th	51.2%
Relative Tail Risk	-12.19%

Reward TTM
Sharpe Ratio	1.08
Alpha	32.10
CAGR/Max DD	-0.08

Character TTM
Hurst Exponent	0.447
Beta	0.274
Beta Downside	0.431

Drawdowns 3y
Max DD	54.64%
Mean DD	29.88%
Median DD	30.39%

Description: CVS CVS Health September 25, 2025

CVS Health Corp. (NYSE:CVS) delivers integrated health-care solutions across three core segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness. The Benefits arm provides a full suite of insurance products-including medical, pharmacy, dental, behavioral health, Medicare Advantage, Medicare Supplement, and Medicaid management-to a diverse client base ranging from large employers to government-sponsored plans.

The Health Services segment operates one of the nation’s largest pharmacy-benefit-management (PBM) platforms, handling plan design, formulary management, specialty and mail-order pharmacy, and disease-management services for employers, insurers, and public-sector sponsors. This PBM business underpins roughly 30% of the U.S. market share for prescription-benefit administration.

Pharmacy & Consumer Wellness runs CVS’s retail footprint of about 9,900 stores, its e-commerce pharmacy sites, long-term-care (LTC) and specialty pharmacies, and a growing compounding and infusion service network. In FY 2023 the segment generated roughly $176 billion in revenue, driven by higher demand for specialty drugs and over-the-counter health-and-beauty products.

Key economic drivers for CVS include the aging U.S. population, which expands Medicare and chronic-disease spending; inflationary pressure on drug pricing that fuels PBM cost-containment initiatives; and the ongoing shift toward integrated, digital health services that can boost cross-selling opportunities across its three segments.

For a deeper, data-driven assessment of CVS’s valuation relative to its peers, you may find ValueRay’s interactive dashboards useful.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (469.0m TTM) > 0 and > 6% of Revenue (6% = 23.65b TTM)

FCFTA 0.02 (>2.0%) and ΔFCFTA 1.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -3.95% (prev -4.69%; Δ 0.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 9.11b > Net Income 469.0m (YES >=105%, WARN >=100%)

Net Debt (72.65b) to EBITDA (10.60b) ratio: 6.85 <= 3.0 (WARN <= 3.5)

Current Ratio 0.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.27b) change vs 12m ago 0.79% (target <= -2.0% for YES)

Gross Margin 13.88% (prev 14.20%; Δ -0.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 155.2% (prev 146.1%; Δ 9.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.94 (EBITDA TTM 10.60b / Interest Expense TTM 3.09b) >= 6 (WARN >= 3)

Altman Z'' 1.15

(A) -0.06 = (Total Current Assets 77.11b - Total Current Liabilities 92.69b) / Total Assets 255.33b

(B) 0.23 = Retained Earnings (Balance) 59.11b / Total Assets 255.33b

(D) 0.60 = Book Value of Equity 109.70b / Total Liabilities 182.22b

Total Rating: 1.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 54.97

1. Piotroski 3.0pt

2. FCF Yield 3.72%

3. FCF Margin 1.60%

4. Debt/Equity 1.12

5. Debt/Ebitda 6.85

6. ROIC - WACC (= 0.51)%

7. RoE 0.62%

8. Rev. Trend 96.86%

9. EPS Trend -52.79%

What is the price of CVS shares?

As of November 30, 2025, the stock is trading at USD 80.36 with a total of 2,292,136 shares traded.
Over the past week, the price has changed by +2.99%, over one month by -2.24%, over three months by +12.31% and over the past year by +40.01%.

Is CVS a buy, sell or hold?

CVS Health has received a consensus analysts rating of 4.21. Therefore, it is recommended to buy CVS.

Strong Buy: 13
Buy: 8
Hold: 7
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CVS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	91.5	13.8%
Analysts Target Price	91.5	13.8%
ValueRay Target Price	93.4	16.2%

CVS Fundamental Data Overview November 26, 2025

Market Cap USD = 98.89b (98.89b USD * 1.0 USD.USD)
P/E Trailing = 205.0
P/E Forward = 11.0132
P/S = 0.2525
P/B = 1.3582
P/EG = 0.6798
Beta = 0.482
Revenue TTM = 394.08b USD
EBIT TTM = 5.99b USD
EBITDA TTM = 10.60b USD
Long Term Debt = 60.51b USD (from longTermDebt, last quarter)
Short Term Debt = 7.24b USD (from shortTermDebt, last quarter)
Debt = 81.75b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 72.65b USD (from netDebt column, last quarter)
Enterprise Value = 169.35b USD (98.89b + Debt 81.75b - CCE 11.29b)
Interest Coverage Ratio = 1.94 (Ebit TTM 5.99b / Interest Expense TTM 3.09b)
FCF Yield = 3.72% (FCF TTM 6.29b / Enterprise Value 169.35b)
FCF Margin = 1.60% (FCF TTM 6.29b / Revenue TTM 394.08b)
Net Margin = 0.12% (Net Income TTM 469.0m / Revenue TTM 394.08b)
Gross Margin = 13.88% ((Revenue TTM 394.08b - Cost of Revenue TTM 339.39b) / Revenue TTM)
Gross Margin QoQ = 13.42% (prev 13.74%)
Tobins Q-Ratio = 0.66 (Enterprise Value 169.35b / Total Assets 255.33b)
Interest Expense / Debt = 0.96% (Interest Expense 784.0m / Debt 81.75b)
Taxrate = -14.59% (negative due to tax credits) (508.0m / -3.48b)
NOPAT = 6.87b (EBIT 5.99b * (1 - -14.59%)) [negative tax rate / tax credits]
Current Ratio = 0.83 (Total Current Assets 77.11b / Total Current Liabilities 92.69b)
Debt / Equity = 1.12 (Debt 81.75b / totalStockholderEquity, last quarter 72.93b)
Debt / EBITDA = 6.85 (Net Debt 72.65b / EBITDA 10.60b)
Debt / FCF = 11.55 (Net Debt 72.65b / FCF TTM 6.29b)
Total Stockholder Equity = 75.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.18% (Net Income 469.0m / Total Assets 255.33b)
RoE = 0.62% (Net Income TTM 469.0m / Total Stockholder Equity 75.70b)
RoCE = 4.40% (EBIT 5.99b / Capital Employed (Equity 75.70b + L.T.Debt 60.51b))
RoIC = 4.85% (NOPAT 6.87b / Invested Capital 141.53b)
WACC = 4.35% (E(98.89b)/V(180.64b) * Re(7.03%) + D(81.75b)/V(180.64b) * Rd(0.96%) * (1-Tc(-0.15)))
Discount Rate = 7.03% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.93%
[DCF Debug] Terminal Value 74.38% ; FCFE base≈4.45b ; Y1≈3.52b ; Y5≈2.35b
Fair Price DCF = 34.40 (DCF Value 43.67b / Shares Outstanding 1.27b; 5y FCF grow -24.86% → 3.0% )
EPS Correlation: -52.79 | EPS CAGR: -5.52% | SUE: 0.72 | # QB: 0
Revenue Correlation: 96.86 | Revenue CAGR: 8.18% | SUE: 0.43 | # QB: 0

Additional Sources for CVS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle